

1 Common genetic variants associated with urinary 2 phthalate levels in children: a genome-wide study

3
4 Mariona Bustamante^{a,b,c,*±}, Laura Balagué^{a*}, Zsanett Buko^d, Amrit Kaur Sakhi^e, Maribel Casas^{a,b,c},
5 Lea Maitre^{a,b,c}, Sandra Andrusaityte^f, Regina Grazuleviciene^f, Kristine B Gützkow^e, Anne Lise
6 Brantsæter^e, Barbara Heude^g, Claire Philippat^h, Leda Chatziⁱ, Marina Vafeiadi^j, Tiffany C Yang^k,
7 John Wright^k, Amy Hough^k, Carlos Ruiz-Arenas^m, Ramil Nurtdinovⁿ, Geòrgia Escaramís^{l,c}, Juan
8 Ramon Gonzalez^{a,b,c}, Cathrine Thomsen^e, Martine Vrijheid^{a,b,c}

9
10 ^aEnvironment and Health over the Lifecourse, ISGlobal, Barcelona, Spain

11 ^bUniversitat Pompeu Fabra (UPF), Barcelona, Spain

12 ^cCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

13 ^dDepartment of Oncological Science, Huntsman Cancer Institute, Salt Lake City, United States of
14 America

15 ^eDivision of Climate and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway

16 ^fDepartment of Environmental Science, Vytautas Magnus University, Kaunas, Lithuania

17 ^gUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Center for Research in
18 Epidemiology and StatisticS (CRESS), F-75004 Paris, France

19 ^hUniversity Grenoble Alpes, Inserm U-1209, CNRS-UMR-5309, Environmental Epidemiology
20 Applied to Reproduction and Respiratory Health Team, Institute for Advanced Biosciences, 38000,
21 Grenoble, France

22 ⁱDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California,
23 Los Angeles, California, USA

24 ^jDepartment of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece

25 ^kBradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust,
26 Bradford, UK

27 ^lDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona (UB), Barcelona,
28 Spain

29 ^mComputational Biology Program, CIMA University of Navarra, Pamplona, 31008, Spain

30 ⁿCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology,
31 Barcelona 08003, Catalonia, Spain

32
33 *Equal contribution

34
35 [±]Corresponding author:

36 Mariona Bustamante

37 mariona.bustamante@isglobal.org

38 ISGlobal

39 Dr. Aiguader 88

40 08003

41 Barcelona
42 Spain

43
44

45 **Highlights**

46

- 47 • The genetic variation involved in phthalate detoxification in humans is partially known.
- 48 • We identified four loci at genome-wide significance, and 113 at suggestive significance, some of
49 them being novel.
- 50 • Two copy number variants were also identified.
- 51 • Functional annotation highlighted genes in phase I and II detoxification and renal excretion.

52

53

54 **Abstract**

55

56 **Introduction:** Phthalates, or diesters of phthalic acid, are a ubiquitous type of plasticizer used in a
57 variety of common consumer and industrial products. They act as endocrine disruptors and are
58 associated with increased risk for several diseases. Once in the body, phthalates are metabolized
59 through partially known mechanisms, involving phase I and phase II enzymes.

60

61 **Objective:** In this study we aimed to identify common single nucleotide polymorphisms (SNPs) and
62 copy number variants (CNVs) associated with the metabolism of phthalate compounds in children
63 through genome-wide association studies (GWAS).

64

65 **Methods:** The study used data from 1,044 children with European ancestry from the Human Early
66 Life Exposome (HELIX) cohort. Ten phthalate metabolites were assessed in a two-void urine pool
67 collected at the mean age of 8 years. Six ratios between secondary and primary phthalate metabolites
68 were calculated. Genome-wide genotyping was done with the Infinium Global Screening Array
69 (GSA) and imputation with the Haplotype Reference Consortium (HRC) panel. PennCNV was used
70 to estimate copy number variants (CNVs) and CNVRanger to identify consensus regions. GWAS of
71 SNPs and CNVs were conducted using PLINK and SNPassoc, respectively. Subsequently, functional
72 annotation of suggestive SNPs (p-value <1E-05) was done with the FUMA web-tool.

73

74 **Results:** We identified four genome-wide significant (p-value <5E-08) loci at chromosome (chr) 3
75 (*FECHP1* for oxo-MiNP_oh-MiNP ratio), chr6 (*SLC17A1* for MECPP_MEHPP ratio), chr9
76 (*RAPGEF1* for MBzP), and chr10 (*CYP2C9* for MECPP_MEHPP ratio). Moreover, 113 additional
77 loci were found at suggestive significance (p-value <1E-05). Two CNVs located at chr11
78 (*MRGPRX1* for oh-MiNP and *SLC35F2* for MEP) were also identified. Functional annotation
79 pointed to genes involved in phase I and phase II detoxification, molecular transfer across
80 membranes, and renal excretion.


81

82 **Conclusion:** Through genome-wide screenings we identified known and novel loci implicated in
 83 phthalate metabolism in children. Genes annotated to these loci participate in detoxification and renal
 84 excretion.

85

86

87 **Graphical abstract:**



88

89 **Keywords:** phthalate, genome-wide association study (GWAS), genetic variant, single nucleotide
 90 polymorphism (SNP), copy number variant (CNV), metabolism, toxicity, phase I and II enzymes,
 91 renal excretion

92

93 **Abbreviations**

94

95 **ABC:** ATP-binding cassette

96 **BBP:** butylbenzyl phthalate

97 **chr:** chromosome

98 **CNV:** copy number variant

99 **CYP:** Cytochrome P450 monooxygenase

100 **DBzP:** dibenzyl phthalate

101 **DEP:** diethyl phthalate

102 **DEHP:** bis(2-ethylhexyl) phthalate

103 **DiBP:** diisobutyl phthalate

104 **DINCH:** 2-cyclohexane dicarboxylic acid, diisononyl ester

105 **DnBP:** di-n-butyl-phthalate

106 **EDCs:** endocrine disrupting chemicals

107 **GSA:** Infinium Global Screening Array

108 **GWAS:** genome-wide association study

109 **HELIX:** Human Early Life Exposome project

110 **HMW:** high-molecular-weight

111 **HRC:** haplotype reference consortium
112 **LD:** linkage disequilibrium
113 **LMW:** low-molecular-weight
114 **MBzP:** mono benzyl phthalate
115 **MECPP:** mono-2-ethyl-5-carboxypentyl phthalate
116 **MECPP_MEHP:** ratio between MECPP and MEHP
117 **MECPP_MEHHP:** ratio between MECPP and MEHHP
118 **MEHHP:** mono-2-ethyl-5-hydroxyhexyl phthalate
119 **MEHHP_MEHP:** ratio between MEHHP and MEHP
120 **MEHP:** mono-2-ethylhexyl phthalate
121 **MEOHP:** mono-2-ethyl-5-oxohexyl phthalate
122 **MEOHP_MEHP:** ratio between MEOHP and MEHP
123 **MEOPP_MEHHP:** ratio between MEOPP and MEHHP
124 **MEP:** monoethyl phthalate
125 **MiBP:** mono-iso-butyl phthalate
126 **MnBP:** mono-n-butyl phthalate
127 **oh-MiNP:** mono-4-methyl-7-hydroxyoctyl phthalate
128 **oxo-MiNP:** mono-4-methyl-7-oxooctyl phthalate
129 **oxo-MiNP_oh-MiNP:** ratio between oxo-MiNP and oh-MiNP
130 **PVC:** polyvinyl chloride
131 **QQ:** quantile-quantile
132 **SCL:** Solute carrier
133 **SNP:** single nucleotide polymorphism
134 **SULT:** Sulfotransferase
135 **UGT:** UDP-glucuronosyltransferase
136
137

138 1. Introduction

139
140 Phthalates, or diesters of phthalic acid, are a ubiquitous type of plasticizer used in a variety of
141 common consumer and industrial products, whose exposure is widespread and ever-changing due to
142 our constantly evolving environment and habits (Praveena et al., 2018; Wang et al., 2019). Phthalates
143 are known to be endocrine disrupting chemicals (EDCs), and epidemiological research has suggested
144 that exposure to phthalates is associated with increased risk for several diseases including infertility,
145 allergy, obesity, diabetes, and behavioral problems (Praveena et al., 2018; Wang et al., 2019). Since
146 children are especially vulnerable to contaminants as they are still developing, there is a great
147 concern over the potential for phthalate exposure to disturb normal growth and development (Braun,
148 2017; Casale and Rice, 2023; Lee et al., 2022, 2023).

149
150 Phthalates can be separated into low-molecular-weight (LMW, 3-6 carbon atoms) and high-
151 molecular-weight (HMW, 7-13 carbon atoms) compounds (Praveena et al., 2018; Wang et al., 2019).
152 LMW phthalates are used as solvents and are usually found in medications and personal care items
153 such as deodorants, lotions, and shampoos. HMW phthalates are used in the manufacturing of
154 flexible plastics for purpose of vinyl flooring, adhesives, medical devices, and food packaging. The
155 main intake of LMW phthalates is through skin and inhalation, while HMW phthalates are
156 incorporated into the body through ingestion (Kim and Park, 2014). In the European Union, some
157 phthalates are now banned from use in cosmetics and regulated in material intended to come into
158 contact with food.

159
160 After exposure, phthalates are rapidly metabolized and excreted mainly in urine as a result of phase I
161 and phase II enzymes (Domínguez-Romero and Scheringer, 2019; Praveena et al., 2018). First,
162 diester phthalates are hydrolyzed to monoester (primary metabolites) by phase I esterase and lipase
163 enzymes (Bhattacharyya et al., 2022). Subsequently, LMW phthalates are primarily excreted in urine
164 and feces as monoesters, without further metabolism. In contrast, HMW phthalates need further
165 metabolism through hydroxylation and oxidation by phase I enzymes thus producing a number of
166 oxidative metabolites (secondary metabolites). These oxidated metabolites can be directly excreted in
167 the urine, or alternatively, can be additionally metabolized through phase II enzymes. Phase II
168 detoxification consists of conjugation reactions where a compound is added to the parental
169 compound to generate hydrophilic conjugates which can then be easily excreted in the urine.
170 Phthalates and their metabolites can be measured in diverse biological specimens, such as blood,
171 urine, breast milk, and feces. However, urinary phthalate metabolites are the most frequently used
172 biomarkers to track exposure to phthalates (Sakhi et al., 2017; Wang et al., 2019).

173
174 Phase I and phase II enzymes are highly polymorphic in humans, with slow and fast metabolic
175 phenotypes determined by single nucleotide polymorphisms (SNPs) and copy number variants
176 (CNVs) (Pinto and Eileen Dolan, 2011). This differential detoxification capacity might modify
177 phthalate effects in the body and is rarely considered in epidemiological studies. In vitro studies
178 demonstrated the importance for phthalate metabolism of genetic polymorphisms in *Cytochrome*
179 *P450 (CYP) monooxygenases*, a family of phase I detoxification enzymes (Choi et al., 2012).

180 Moreover, in humans, urinary phthalate metabolite levels were reported to be associated with genetic
181 variants in *CYP monooxygenases* (*CYP2C9* and *CYP2C19*) and in *UDP-glucuronosyltransferases*
182 (*UGT1A7*) in young adults (Stajanko et al., 2022), and with variants in *GSTP1* and *SOD2* in children
183 (Wang and Karmaus, 2017). However, these studies were based on a priori knowledge of candidate
184 genes and SNPs, likely missing additional loci important for phthalate metabolism. Genome-wide
185 association studies (GWAS), which allow the interrogation of millions of common genetic variants,
186 both SNPs and CNVs, can help to overcome this limitation and reveal new phthalate detoxification
187 pathways (Visscher et al., 2017).

188

189 Here, we aimed to identify genetic variants related to phthalate metabolism in children. For this, we
190 analyzed the association of genome-wide SNPs and CNVs with urinary levels of ten phthalate
191 metabolites and six phthalate ratios in 1,044 European ancestry children from the Human Early Life
192 Exposome (HELIX) project and performed functional annotation of the identified variants.

193

194

195 **2. Materials and methods**

196

197 *2.1. Study population*

198

199 HELIX project is an ongoing population-based birth control study in six birth cohorts from different
200 European countries: (1) EDEN - Étude des Déterminants pré et postnatals du développement et de la
201 santé de l'enfant, France; (2) Rhea - the Rhea Mother-Child Study in Crete, Greece; (3) KANC -
202 Kaunus Cohort, Lithuania; (4) MoBa - the Norwegian Mother, Father and Child Cohort Study,
203 Norway; (5) INMA - - Infancia y Medio Ambiente, Spain; (6) BiB - Born in Bradford, United
204 Kingdom (UK) (Maitre et al., 2018). The HELIX project aims to implement novel exposure
205 assessment and biomarker methods to measure the early-life exposure to multiple environmental
206 factors and associate these with omics biomarkers and child health outcomes, thus characterizing the
207 “early-life exposome”. The entire study population is 31,472 mother-child pairs. The subcohort study
208 includes 1,304 children with exposure, phenotypes, and molecular data measured at age of 6-12
209 years. The current study selected 1,044 children of European ancestry with genome-wide genetic and
210 phthalate metabolite levels available from the HELIX subcohort (Appendix A - Supplementary
211 Figure 1). Child’s ancestry was predicted from genome-wide genetic data. The following variables
212 were used to describe the population: child’s sex (male/female), child’s age (in years), child’s obesity
213 in 3 categories (normal, overweight, obese) based on the World Health Organization (WHO) body
214 mass index (BMI) classification, and self-reported maternal education (primary, secondary and
215 university or higher).

216

217 *2.2. Ethics approval and consent to participate*

218

219 All studies were approved by the national research ethics committees and informed consent to
220 participate was obtained for all participants.

221

222 2.3. Phthalate biomarkers measurement

223
224 Metabolites for 6 different phthalates were measured in a pool of two urine samples collected in the
225 morning and at bedtime at the mean age of 8 years (Figure 1).

226
227 An aliquot of the urine pool was analyzed for the determination of four LMW primary phthalate
228 metabolites [monoethyl phthalate (MEP), mono-n-butyl phthalate (MnBP), mono-isobutyl phthalate
229 (MiBP), mono benzyl phthalate (MBzP)], one HMW primary phthalate metabolite [mono-2-
230 ethylhexyl phthalate (MEHP)], and five HMW secondary metabolites [mono-2-ethyl-5-
231 hydroxyphenyl phthalate (MEHHP), mono-2-ethyl-5-oxohexyl phthalate (MEOHP), mono-2-ethyl-5-
232 oxyhexyl phthalate (MECPP), mono-4-methyl-7-hydroxyoctyl phthalate (oh-MiNP), and
233 mono-4-methyl-7-oxooctyl phthalate (oxo-MiNP)], using high performance liquid chromatography
234 coupled to mass spectrometry (Haug et al., 2018). Both external control samples, in-house control
235 samples and blank samples were analyzed in each batch of about fifty samples. The limits of
236 detection (LOD) of the method ranged from 0.067 to 0.67 ng/mL. All the samples had values >LOD.
237 MEHP, MEHHP and MEOHP had 34, 3 and 1 missing values, due to underperformance of sample
238 quantification.

239
240 To account for urine dilution, a second aliquot of urine was analyzed for creatinine concentration,
241 and phthalate metabolite concentrations were divided by urinary creatinine levels (Haug et al., 2018).
242 All creatinine-adjusted concentrations were log₂ transformed to obtain normal distributions, as the
243 original distributions were right-skewed. Finally, as a proxy of enzymatic activity, we calculated six
244 ratios between product and substrate, in our case, between secondary and primary phthalate
245 metabolites or between two secondary phthalate metabolites, as follows: MECPP_MEHP,
246 MEHHP_MEHP, MEOHP_MEHP, MECPP_MEHHP, MEOHP_MEHHP and oxo-MiNP_oh-MiNP.
247 The ratios were calculated using untransformed phthalate values unadjusted for creatinine, and then
248 they were log₂ transformed. Urine dilution was not taken into account as the ratios were computed
249 using two compounds within the same urine sample.

250 2.4. Genetic data

251
252
253 DNA was obtained from buffy coats collected in EDTA tubes at the mean age of 8 years. DNA was
254 extracted by cohort using a Chemagen kit in batched of 12 samples. Two techniques were used to
255 determine the DNA concentration 1) NanoDrop 1000 UV-Vis Spectrophotometer (ThermoScientific)
256 and 2) Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies).

257
258 Infinium Global Screening Array (GSA) MD version 1 (Illumina) was used for genome-wide
259 genotyping at the Human Genomics Facility (HuGe-F), Erasmus MC (www.glimdna.org). Genotype
260 calling and annotation were done using the GenTrain2.8 algorithm based on a custom cluster file
261 implemented in the GenomeStudio software and the GSAMD-24v1-0_20011747-A4 manifest. SNP
262 coordinates were reported on human reference GRCh37 and on the source strand.

263

264 PLINK program was used for the quality control of the genetic data (Purcell et al., 2007). Briefly,
265 samples were filtered out if they had a call rate <97%, had sex inconsistencies, the heterozygosity
266 was >3 standard deviations, if they were related (sharing >18.5% of alleles) or duplicated. For
267 ancestry prediction from GWAS data, we used the Peddy program (Pedersen and Quinlan, 2017).
268 Then genetic ancestry was contrasted with self-reported ethnicity and discordant samples were
269 excluded. Genetic variants were filtered out if they had a call rate <95%, if they were in the non-
270 canonical pseudo-autosomal region (PAR), if they had a minor allele frequency (MAF) <1%, and if
271 they were not in Hardy-Weinberg equilibrium (HWE) at a p-value <1E-06. PLINK was also used to
272 compute the first 20 principal components from the GWAS data of European ancestry children using
273 the linkage disequilibrium (LD) clumping option. Ten PCs explained up to 19.2% of the genetic
274 variance and the five first ones correlated with cohort.

275
276 Genome-wide imputation was performed with the Imputation Michigan server using the Haplotype
277 Reference Consortium (HRC) panel, Version r1.1 2016. Before the imputation PLINK data was
278 converted into VCF format and the variants were aligned with the reference genome. Eagle v2.4 was
279 used for the phasing of the haplotypes and minimac4 for the imputation. In the end, we retrieved
280 40,405,505 variants after imputation. Then we filtered out the genetic variants according to the
281 following parameters: imputation accuracy (R2) <0.9, MAF<5%, and HWE p-value <1E-06. After
282 this the post-imputation dataset had 4,614,947 variants.

283 284 *2.5. GWAS of SNPs*

285
286 GWAS of SNPs were conducted with the PLINK program by applying a linear regression model for
287 each phthalate metabolite and each SNP from chromosome 1 to 22, adjusting for sex, age and ten
288 GWAS principal components as a proxy of ancestry (PCs) (Purcell et al., 2007). We run a total of 16
289 GWAS (five primary metabolites, five secondary metabolites, and six ratios). Genome-wide
290 statistical significance was established at a p-value <5E-08, and suggestive statistical significance at
291 a p-value <1E-5. The lambda genomic inflation factor was estimated as the median of the resulting
292 chi-squared test statistics divided by the expected median of the chi-squared distribution. Quantile-
293 quantile (QQ) plots were conducted with the ggplot2 package and Manhattan plots were conducted
294 with the qqman package in R (D. Turner, 2018; Wickham, 2016). The lead SNP is defined as the
295 SNP with the lowest p-value in a locus, and a locus is defined as a region of 1Mb.

296
297 In order to filter out associations between the SNPs and creatinine levels, we run sensitivity models
298 adjusting for log2 transformed creatinine levels, instead of controlling (dividing) the phthalate
299 concentrations by creatinine. Finally, we also run a GWAS for log2 transformed creatinine levels (g
300 per L of urine).

301 302 *2.6. GWAS of CNVs*

303
304 Copy number variant (CNV) calls were obtained with PennCNV using BAF/LRR signal files from
305 Illumina BeadStudio (Wang et al., 2007). A total of 22 samples from the initial 1,044 had to be

306 removed due to poor quality in BAF or LRR values. After that, CNV calls overlapping with the
307 centromeres were filtered out. After the quality control, consensus CNV regions were obtained with
308 the CNVRanger R package following the reciprocal overlap procedure, that merges calls with
309 sufficient mutual overlap, in our case 50% (Conrad et al., 2010; Da Silva et al., 2020). From the
310 resulting consensus regions, only common CNVs with an alternative minor allele frequency (either
311 gain or loss) >3% were kept for the analysis. Consensus CNV regions were classified into: (i) only
312 loss, when we only detected deletions (CN=0 and CN=1); (ii) only gain, when we only detected
313 duplications (CN=3; note that more than 3 copies were never detected); and (iii) loss and gain, when
314 we detected both deletions and duplications (CN=0, CN=1 and CN=3).

315
316 Association analyses between each of the resulting regions and each of the 16 metabolites and ratios
317 were performed with SNPAssoc R package (González et al., 2007). Distinct association models were
318 applied to each region based on the prior CNV classification. For only-loss regions we tested loss-
319 codominant (0 vs 1 vs 2), loss-dominant (0+1 vs 2), loss-recessive (0 vs 1+2), loss-overdominant
320 (0+2 vs 1) and loss-log-additive models; and for only-gain regions we tested gain-codominant (2 vs
321 3) model. Finally, for loss-and-gain regions we tested all loss-specific and gain-specific models
322 above, as well as an additive lineal model taking into account loss and gain. All analyses were
323 adjusted for the same covariates as the GWAS of SNPs (sex, age and ten GWAS principal
324 components (PCs)). Multiple-testing correction was conducted by dividing the nominal p-value of
325 0.05 by the number of detected consensus CNVs ($0.05/36 = 0.0014$). As was done with SNPs,
326 sensitivity models adjusting for log₂ transformed creatinine levels were investigated in order to filter
327 out associations between the CNVs and creatinine levels. Finally, we also run a model for log₂
328 transformed creatinine levels (g per L of urine).

329
330 Annotation of genes in each CNV region was done with the biomaRt R package (Durinck et al.,
331 2009).

332
333

334 *2.7. Functional annotation of genetic variants, gene-wide association analysis and enrichment*

335
336 For the annotation, prioritization, and biological interpretation of the genetic variants identified in the
337 GWAS, we used the Functional Mapping and Annotation of Genome-Wide Association Studies
338 (FUMA) tool (Watanabe et al., 2017). The SNP2GENE module computes LD structure, annotates
339 SNPs using information from different databases, and prioritizes candidate genes. FUMA was run
340 using default parameters except that the p-value threshold was set to 1E-05 instead of 1E-08. For the
341 SNP annotation we used: ANNOVAR, CADD, RegulomeDB, expression quantitative trait locus
342 (eQTL) mapping based on Genotype-Tissue Expression (GTEx) v8 and other databases, comparison
343 with SNPs reported in the GWAS catalog and gene mapping through chromatin interaction maps.
344 Then, with the GENE2FUNC module from FUMA prioritized genes from SNP2GENE module were
345 used to identify shared molecular functions using different databases: Gene Ontology (GO) terms,
346 Kyoto Encyclopedia of Genes and Genomes (KEGG), and Reactome, among others. GENE2FUNC
347 was also used to assess enrichment for 54 tissues included in the GTExv8 dataset.

348
349 For gene mapping through chromatin interaction we also used the EPIraction tool (Nurtdinov and
350 Guigó, n.d.). Briefly, the tool contains a catalogue of tissue specific gene-enhancer interactions
351 identified by applying linear models between gene expression and activities of nearby enhancers
352 across 1,529 samples from 77 different tissues. In this study, we annotated SNPs to enhancers and
353 then linked enhancers to genes in two candidate tissues for phthalate detoxification: liver and
354 kidney.

355

356

357 **3. Results**

358

359 *3.1. Description of the population*

360

361 The description of the 1,044 HELIX participants is shown in Table 1. All participants were of
362 European ancestry and from six different countries: Greece, Norway, Spain, Lithuania, France, and
363 the UK. Forty-six percent of the participants were female, and the mean age of phthalate
364 measurements was 8 years (standard deviation (SD): 1.6). Around half of the children were born
365 from highly educated mothers. Urinary phthalate levels (micrograms (μg) per gram (g) of creatinine)
366 were in the range or higher than levels reported in children and adolescents from 12 European
367 countries for the period 2014–2021 (Vogel et al., 2023). After \log_2 transformation, levels tended to
368 be normally distributed and the correlation among them ranged from 0.18 to 0.98 (Appendix A –
369 Supplementary Figure 2). Highest correlations ($r > 0.79$) were observed among MECPP, MEHHP,
370 MEOHP, MEHP, which are all primary or secondary metabolites of the same parental compound,
371 DEHP. The correlation of oh-MiNP and oxo-MiNP was also high ($R = 0.73$).

372

373 *3.2. GWAS of SNPs*

374

375 To identify SNPs associated with the detoxification metabolism of phthalates in children, we run
376 linear regressions for each of the ten phthalate metabolites and the six metabolic ratios adjusting for
377 sex, age, and 10 GWAS principal components.

378

379 Genomic inflation factors (lambdas) ranged from 0.989 to 1.021 (Appendix A – Supplementary
380 Figure 3). Four loci reached genome-wide significance ($p\text{-value} < 5\text{E-}08$) as shown in the Miami plot
381 (Figure 2). They involved two SNPs at chr3 associated with the oxo-MiNP_oh-MiNP ratio (lead SNP
382 rs80064213_C, effect = 0.331, $p\text{-value} = 4.15\text{E-}08$, near *FECHP1* gene), 116 SNPs at chr6
383 associated with the MECPP_MEHPP ratio (rs1359232_A, effect = -0.134, $p\text{-value} = 4.58\text{E-}17$,
384 *SLC17A1*), one SNP at chr9 associated with MBzP (rs138702233_T, effect = 0.394, $p\text{-value} = 4.29\text{E-}$
385 08 , *RAPGEF1*), and 658, 186 and 369 SNPs at chr10 associated with the MECPP_MEHPP,
386 MEOHP_MEHHP and MECPP_MEHP ratios, respectively (rs74494115_T, effect = -0.309, $p\text{-value}$
387 $= 1.45\text{E-}63$, *CYP2C9*). The locus zoom plots of these four loci are shown in Figure 3.

388

389 Moreover, 2,140 SNPs representing 158 loci (113 unique) were identified at suggestive significance
390 (p-value <1E-05) for at least one phthalate metabolite or ratio (Table 2, Appendix B - Supplementary
391 Table B1). The number of loci with suggestive statistical significance per phthalate metabolite or
392 ratio was between five and 15. Thirty of the 117 suggestive or genome-wide significant unique loci
393 were shared between more than one phthalate compound or ratio (Appendix A – Supplementary
394 Figure 4). The genome-wide significant loci at chr3 (*FECHP1*), chr6 (*SLC17A1*) and chr10
395 (*CYP2C9*), also had suggestive associations with other phthalate compounds or ratios (Table 3,
396 Appendix B – Supplementary Table B1).

397
398 Sensitivity analysis adjusting for creatinine instead that using it to divide phthalate metabolite levels
399 gave similar results with minor differences (Appendix B - Supplementary Table B2). Three of the
400 four genome-wide significant loci had still a p-value <1E-08, and the other hit (chr9 loci associated
401 with MBzP) was marginally significant (p-value = 9.95E-07). A plot comparing p-values and effect
402 sizes between the two models for all the suggestive SNPs can be seen at Appendix A –
403 Supplementary Figure 5A and 5B. Moreover, the GWAS of creatinine levels did not retrieve any
404 genome-wide significant SNP. Only two of the creatinine suggestive SNPs were also suggestively
405 associated with MEOHP and oh-MiNP (Appendix B Supplementary Table B19).

406 407 3.3. GWAS of CNVs

408
409 Using the PennCNV tool, we identified a median of seven (interquartile range (IQR): 6-9) CNV
410 regions per child with a median length of 43 (IQR: 29-64) kb. Only two children did not present any
411 CNV event. After applying a reciprocal overlap of 50%, 2,916 distinct CNV regions were detected,
412 including 1,785 that were unique, meaning that they were detected in only one child. Thirty-six of the
413 2,916 CNVs were identified in > 3% of the children and thus labeled as consensus CNV regions and
414 tested in relation to phthalate levels and ratios (Appendix C – Supplementary Table C0).

415
416 In 12 of the 36 consensus regions, we detected single or double deletions (loss CNVs, CN=0 and
417 CN=1), in seven of them we detected single duplications (gain CNVs, CN=3) and in 17 of them we
418 detected single and double deletions as well as single duplications (loss and gain CNVs, CN=0,
419 CN=1 and CN=3). We did not detect double duplications (CN=4) in any CNV consensus region.
420 Different models were tested in each type of region (see 2.6.) and the model with the highest
421 significance was reported for each region. The results of the association of these common CNVs with
422 phthalate levels and ratios can be found in Appendix C – Supplementary Tables C3-18.

423
424 Fifty-one CNVs presented nominal significance and two of them passed multiple-testing correction
425 (Figure 2, Appendix C - Supplementary Table C1). First, a single-copy gain in CNV region 11A was
426 associated with higher oh-MiNP levels (chr11:18.95Mb-18.96Mb_gain, effect = 1.231, p-value =
427 1.77E-06, *MRGPRX1* gene), and second, a single-copy gain in CNV region 11B was associated with
428 higher MEP levels (chr11:107.65Mb-107.67Mb_gain, effect = 0.792, p-value = 1.36E-03, *SLC35F2*).
429 The locus zoom plots of these two CNVs are shown in Figure 4.

430

431 In the sensitivity analysis adjusting for creatinine, the 88% of the nominally significant associations
432 were reproduced (45 of 51). The associations between CNV 11A and oh-MiNP and between CNV
433 11B and MEP were very similar (Appendix C - Supplementary Table C2), however the later did not
434 reach the multiple-testing threshold (chr11:18.95Mb-18.96Mb_gain, effect = 1.120, p-value = 2.51E-
435 06; chr11:107.65Mb-107.67Mb_gain, effect = 0.695, p-value =1.48E-03). A plot comparing p-values
436 and effect sizes between the two models for all the suggestive CNVs can be seen at Appendix A –
437 Supplementary Figure 5C and 5D. Results for creatinine GWAS did not show any significant
438 association, with only four CNV regions, not including 11A and 11B, showing a p-value <0.05
439 (Appendix C - Supplementary Table C19).

440

441 *3.4. Functional annotation of genetic variants and identification of candidate genes and pathways*

442

443 Next, SNPs with suggestive significance were explored with the FUMA tool providing information
444 on SNP annotation (Appendix D), identification of eQTLs (Appendix E), and comparison with SNPs
445 in the GWAS catalog (Appendix F). Appendix G shows the list of candidate genes in each locus
446 based on FUMA results and gene-enhancer interactions from the EPIraction tool. A selection of 12
447 interesting loci in terms of statistical significance, annotated genes and/or overlap with GWAS traits
448 is listed in Table 3. These loci are annotated to phase I and phase II detoxification genes [*CYP*
449 *monooxygenases* (*CYP2C* cluster), *Sulfotransferases* (*SULT1B1*, *SULT1E1*, and *SULT1C3*), *UDP*
450 *glucuronosyltransferases* (*UGT2A1*, *UGT2A2* and *UGT2B11*), and glutathione related genes (*GSR*,
451 *GPX5* and *GPX6*)]; and genes related to molecule transport across membranes [*Solute carriers*
452 (*SLC17A* cluster, *SLC8A2*, and *SLC35G1*) and others such as *ABCC3*, *ATP9B* and *STAC*].

453

454 After the FUMA annotation, we took suggestive prioritized genes to run gene-set enrichment
455 analyses (Appendix H). Among others, we identified gene-sets related to xenobiotic detoxification,
456 drug detoxification, CYP, oxidoreductase reactions, liver, phase I and phase II enzymes. These gene-
457 sets were found basically for MEP, MECPP and its ratios, and MEOHP ratios.

458

459 Finally, we searched for enriched GTExv8 tissues (Appendix I). At adjusted and/or nominal
460 statistical significance, we found enrichment for candidate tissues involved in phthalate metabolism:
461 liver (MEOHP_MEHP and MEOPH_MEHHP), kidney cortex (MBzP, MECPP_MEHP and
462 MEOHP_MEHHP), and bladder (MECPP_MEHP). Other significant enrichments were found for
463 skin and vagina (oxo-MiNP_oh-MiNP), artery aorta (MiBP), and nerve tibial (MEHP).

464

465 **4. Discussion**

466

467 In this study we conducted genome-wide screenings of SNPs and CNVs in order to identify genetic
468 variation associated with phthalate metabolism in children. We identified four genome-wide
469 significant loci at chr3 (*FECHP1* – oxo-MiNP_oh-MiNP), chr6 (*SLC17A1* – MECPP_MEHPP), chr9
470 (*RAPGEF1* – MBzP) and chr10 (*CYP2C9* – MECPP_MEHPP) and two significant CNVs located at
471 chr11 (*MRGPRX1* – oh-MiNP and *SLC35F2* – MEP). Functional annotation of suggestive SNPs
472 highlighted pathways related to xenobiotic and drug detoxification. Also some of the genes annotated

473 to the SNPs associated with phthalates showed significant enrichment for key tissues as liver and
474 kidney, which is indicative of high gene expression levels in these tissues. Furthermore, previous
475 GWAS have reported significant associations of SNPs located in these loci with drug
476 biotransformation and urinary metabolite levels of several compounds. Below we describe in detail
477 the most relevant loci and genes identified, which are related to phase I and II metabolism, transport
478 of molecules across membranes and kidney function.

479

480 *4.1. Phase I metabolism*

481

482 We identified three loci annotated to *CYP* genes, one of them achieving the smallest p-value of the
483 study. This top locus at chr10 was associated with four DEHP metabolite ratios (MECPP_MEHPP;
484 MECPP_MEHP; MEOHP_MEHHP; MEOHP_MEHP) and contains *CYP2C8*, *CYP2C9*, *CYP2C18*,
485 and *CYP2C19* genes. According to the EPIraction tool, the locus can act as an enhancer of these
486 genes in liver and/or kidney. *CYP* genes code for phase I monooxygenases that are key in multitude
487 of metabolic processes of endogenous and exogenous compounds, and, indeed, SNPs in this locus
488 have previously been reported to be associated with serum or plasma levels of several metabolites or
489 proteins (Feofanova et al., 2020; Pazoki et al., 2021; Schlosser et al., 2020) and drug response (ie.
490 warfarin) (Takeuchi et al., 2009). Moreover, CYP2C enzymes are known to participate in phthalate
491 metabolism, and *CYP2C9* variants have been associated with the biotransformation of MEHP into
492 secondary metabolites in young adults (Stajnko et al., 2022). Our study confirms that similar
493 detoxification mechanisms take place in children. The two additional *CYP* loci, one at chr7 harboring
494 *CYP2W1* and the other at chr19 including *CYP2A6*, *CYP2B6*, *CYP2A13* and *CYP2S1*, showed
495 suggestive associations with urinary MEP levels (metabolite of diethyl phthalate (DEP)). Therefore,
496 according to our results, DEP (LMW phthalate present in many personal care products, particularly
497 those containing fragrances) and DEHP (HMW phthalate mainly used for food packaging) seem to
498 be metabolized through different CYP genes.

499

500

501 *4.2. Phase II metabolism*

502

503 We also identified several loci annotated to phase II metabolism genes, including
504 *UDP-glucuronosyltransferases (UGTs)*, *Sulfotransferases (SULTs)* and *Glutathione S-transferases*
505 (*GSTs*). First, we found a locus at chr4, annotated to *UGT2B11*, *UGT2A1* and *UGT2A2*, to be
506 suggestively associated with levels of MnBP, a metabolite of di-n-butyl-phthalate (DnBP), which is
507 found in paints, adhesives, personal care products and deodorants. SNPs in another family member,
508 *UGT1A7*, were previously related to urinary levels of 2-cyclohexane dicarboxylic acid, diisononyl
509 ester (DINCH) metabolite in men and of diisobutyl phthalate (DiBP) and dibenzyl phthalate (DBzP)
510 metabolites in women (Stajnko et al., 2022). Notably, DiBP and DnBP are structural isomers.
511 Second, we found three loci annotated to *Sulfotransferases*: the same locus at chr4 associated with
512 MnBP also contained the *SULT1B1* and *SULT1E1* genes, and two additional suggestive loci at chr2
513 and chr19 harboring SNPs near *SULT1C3* and *SULT2B1* genes, respectively, that showed
514 associations with DEHP metabolites. Previous studies have described that multiple phthalates have

515 strong inhibition potential towards *SULT* enzymes, potentially causing reduced body detoxification
516 and liver injury (Ceauranu et al., 2023; Huang et al., 2022). Finally, we identified two loci that
517 contain genes that participate in the glutathione metabolism: a genome-wide significant locus at chr6
518 annotated to *GPX5*, *GPX6* and *SLC* genes associated with MEHP and oh-MiNP levels; and a
519 suggestive locus at chr8 near *GSR*, a central enzyme of cellular antioxidant defence, associated with
520 MEHP ratios. This is consistent with previous research reporting that in zebrafish, MEHP exposure
521 alters the expression of *gsr* (Kwan et al., 2021).

522

523 *4.3. Molecular transport across membranes and kidney function*

524

525 Besides detoxification, we identified several loci annotated to transmembrane transporter genes
526 which could potentially play a role in the excretion of phthalates in the intestine or kidney. These
527 encompass several *Solute carrier (SLC)* genes that code for transporters of a wide array of substrates
528 across membranes (Liu, 2019). A locus at chr6 harboring *SLC17A1*, *SLC17A2*, *SLC17A3* and
529 *SLC17A4* was associated with MEHP ratios at genome-wide significance and showed suggestive
530 associations with oh-MiNP. Both gene-enhancer and eQTL information, suggested that these SNPs
531 regulate *SLC* expression in liver and/or kidney. Moreover, it is known that *SLC17A1* and *SLC17A3*
532 participate in urate regulation by facilitating the excretion of intracellular urate from the bloodstream
533 into renal tubule cells. Consistently, previous GWAS reported associations between this locus and
534 serum uric acid levels (Hollis-Moffatt et al., 2012), urinary metabolite levels (Schlosser et al., 2020),
535 estimated glomerular filtration rate (creatinine) (Stanzick et al., 2021), and chronic kidney disease
536 (Torres et al., 2021), among others. Besides, other associations involving the *SLC* family were
537 identified, including the association between a single-copy gain in a CNV that overlaps the final exon
538 and 3'UTR of the *SLC35F2* gene, predicted to enable transmembrane transporter activity, and MEP
539 urinary levels.

540

541 *ABCC3* encodes a member of the ATP-binding cassette (ABC) transporters that play a role in the
542 transport of biliary and intestinal excretion of organic anions. Moreover, it is reported to be involved
543 in multi-drug resistance (Deeley et al., 2006; Ramírez-Cosmes et al., 2021) and variants in the gene
544 are related to serum/plasma metabolite levels (Bruhn and Cascorbi, 2014). In our study, SNPs in the
545 *ABCC3* intronic region (chr17) were found to be suggestively associated with the MEOHP_MEHP
546 ratio. Notably, another study showed that flies exposed to dibutyl-phthalate (DBP) have increased
547 expression of several genes, including an homologous of the *ABCC3* gene (Williams et al., 2016).
548 Two more transporters were identified. On the one hand, SNPs in a liver and kidney enhancer for
549 *ATP9B* gene (chr18), which is predicted to enable ATPase-coupled intramembrane lipid transport,
550 were suggestively associated with DEHP metabolites and ratios. On the other hand, SNPs near *STAC*
551 (chr3) were associated with the oxo-MiNP_oh-MiNP ratio at genome wide significance and with the
552 MEOHP_MEHHP ratio at suggestive significance. *STAC* is predicted to enable transmembrane
553 transporter binding activity and participate in positive regulation of voltage-gated calcium channels
554 and skeletal muscle contraction.

555

556 The last group of results is comprised by two genes potentially implicated in kidney function:
557 *RAPGEF1* and *MRGPRX1*. First, SNPs located in a liver and kidney enhancer for *RAPGEF1* at chr9
558 were genome-wide associated with MBzP, a metabolite of butylbenzyl phthalate (BBP) used as
559 plasticizer for polyvinyl chloride (PVC). *RAPGEF1* encodes a guanine nucleotide exchange factor,
560 and mutations in genes of the same family have been found in patients with nephrotic syndrome type
561 7 and membranoproliferative glomerulonephritis (Maywald et al., 2022; Zhu et al., 2019). Second, a
562 loss-gain CNV of 10.8 kb overlapping the whole gene *MRGPRX1* was associated with oh-MiNP, a
563 metabolite of DINP which is used primarily in the manufacture of PVC. *MRGPRX1* encodes a Mas-
564 related G-protein-coupled receptor reported to be responsible for itch sensation, pain transmission
565 and inflammatory reactions, including those to the antimalarial drug chloroquine (Gan et al., 2023).
566 Additionally, mutations in other G-protein-coupled receptors have been implicated in nephrogenic
567 diabetes insipidus, a disease characterized by polyuria and polydipsia (Wang et al., 2018). We found
568 that individuals with three copies of the gene had increased levels of urinary levels of oh-MiNP,
569 whereas individuals with zero or one copy had no difference versus the reference group with two
570 copies. Given the low numbers presenting the alternative allele, further investigation in a larger
571 sample would be required.

572
573 Our study found several associations between phthalates and SNPs known to regulate urinary
574 metabolite levels, glomerular filtration rate, and kidney function. These associations might indicate a
575 real participation of these SNPs in phthalate excretion. Nevertheless, as our phthalate measurements
576 were normalized by creatinine to account for urine dilution, some of our results could also just reflect
577 renal excretion capacity. Although both explanations are possible, there is some evidence supporting
578 the former. First, in vitro studies suggest that phthalates can be a substrate for the *SLC* transporters
579 (Klaassen and Aleksunes, 2010); second, the associations found with the phthalate ratios are
580 unaffected by the creatinine normalization; third the sensitivity model adjusting for creatinine instead
581 of normalizing by it provided similar results; and four the GWAS of creatinine did not found many
582 suggestive loci overlapping with loci found for phthalates.

583 584 4.4. Strengths of the study

585
586 The study has several strengths. First, we measured a large number of phthalate metabolites using a
587 robust analytical method in an equal volume daily pool of two urine samples (morning and night).
588 Second, instead of analyzing individual SNPs in candidate genes, we performed genome-wide
589 screenings of SNPs and CNVs and several downstream annotation methods that allowed us to
590 identify novel loci implicated in phthalate metabolism. Although some genes seemed to be involved
591 in detoxification of more than one phthalate compound (ie. *SULT1C3* for MnBP and MEHP, or
592 *SLC17* for oh-MiNP and MEHP), others appeared to be more specific (ie. *CYP2C* for MEHP while
593 *CYP2A* for MEP). Third, the study was conducted in a large sample of children from the HELIX
594 project, higher than previous similar studies but still limited in comparison with GWAS of other
595 traits. This study, besides producing novel knowledge about the genes participating in phthalate
596 detoxification and renal excretion, also provides a list of SNPs that can be used to stratify individuals
597 in epidemiological research. Bearing the “alternative” alleles of these SNPs can confer different

598 susceptibility to phthalate's effects depending on the SNP function (i.e., fast biotransformation to a
599 neutral compound and then excretion versus fast biotransformation to a more toxic compound).

600

601 *4.5. Limitations of the study*

602

603 However, the study also has some limitations. First, we have restricted our discussion on few genes
604 with interesting functions for phthalate metabolism. However, since SNPs can regulate long distance
605 genes, other genes not highlighted here could also be relevant. Functional analyses in in vitro studies
606 or animal models should be conducted in order to identify the causal variants and genes. Second, we
607 analyzed phthalate metabolites in a pool of two urines and then standardized for creatinine. This has
608 some limitations, especially for pooled samples as discussed elsewhere (O'Brien et al., 2017;
609 Philippat and Calafat, 2021), but currently there is no consensus on how to account for urine dilution
610 in equal volume pools. As discussed above, this could have resulted in the identification of genetic
611 variants that regulate glomerular filtration in general, rather than phthalate excretion in particular.
612 Finally, the analyses were restricted to European ancestry children, thus the translation to other
613 ancestries is unknown.

614

615 **5. Conclusions**

616

617 In summary, through genome-wide screenings we identified known and novel loci potentially
618 implicated in phthalate metabolism in children. Genes annotated to these loci participate in phase I
619 and phase II metabolism and renal excretion process. Replication of the findings in independent
620 studies and validation in in vitro systems is required.

621

622 **6. Competing Interests**

623

624 The authors declare that the research was conducted in the absence of any commercial or financial
625 relationships that could be construed as a potential conflict of interest.

626

627 **7. Author Contributions**

628

629 MB conceptualized the study. MB, LB, ZB, and RN conducted the statistical analysis or functional
630 enrichment analysis with the support of JRG. The HELIX project was coordinated by MV with the
631 support of LM. SA, ALB, MAC, MC, LC, RG, KBG, BH, JL, JS, TCY, JW, are the PIs of the
632 cohorts or participated in sample or data acquisition. AKS was responsible for measurement of
633 phthalate metabolites. MB, GE and CRA participated in genetic data acquisition. LB, ZB and MB
634 wrote the original draft of the paper and all the other co-authors contributed to reviewing and editing
635 the manuscript.

636

637 **8. Acknowledgements**

638

639 We would like to thank all the families for their generous contribution.

640

641 9. Funding

642

643 The study has received funding from the European Community's Seventh Framework Programme
644 (FP7/2007-2013) under grant agreement no 308333 (HELIX project) and the H2020-EU.3.1.2. -
645 Preventing Disease Programme under grant agreement no 874583 (ATHLETE project). The
646 genotyping was supported by the project PI17/01225 and PI17/01935, funded by the Instituto de
647 Salud Carlos III and co-funded by European Union (ERDF, "A way to make Europe") and the Centro
648 Nacional de Genotipado-CEGEN (PRB2-ISCI).

649

650 BiB received core infrastructure funding from the Wellcome Trust (WT101597MA) and a joint grant
651 from the UK Medical Research Council (MRC) and Economic and Social Science Research Council
652 (ESRC) (MR/N024397/1), and National Institute for Health Research Applied Research
653 Collaboration Yorkshire and Humber (NIHR200166). The views expressed are those of the author(s),
654 and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. INMA
655 data collections were supported by grants from the Instituto de Salud Carlos III, CIBERESP, and the
656 Generalitat de Catalunya-CIRIT. KANC was funded by the grant of the Lithuanian Agency for
657 Science Innovation and Technology (6-04-2014_31V-66). The Norwegian Mother, Father and Child
658 Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry
659 of Education and Research. The Rhea project was financially supported by European projects (EU
660 FP6-2003-Food-3-NewGeneris, EU FP6. STREP Hiwate, EU FP7 ENV.2007.1.2.2.2. Project No
661 211250 Escape, EU FP7-2008-ENV-1.2.1.4 Envirogenomarkers, EU FP7-HEALTH-2009- single
662 stage CHICOS, EU FP7 ENV.2008.1.2.1.6. Proposal No 226285 ENRIECO, EU- FP7- HEALTH-
663 2012 Proposal No 308333 HELIX), and the Greek Ministry of Health (Program of Prevention of
664 obesity and neurodevelopmental disorders in preschool children, in Heraklion district, Crete, Greece:
665 2011-2014; "Rhea Plus": Primary Prevention Program of Environmental Risk Factors for
666 Reproductive Health, and Child Health: 2012-15). ISGlobal acknowledges support from the Spanish
667 Ministry of Science and Innovation through the "Centro de Excelencia Severo Ochoa 2019-2023"
668 Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA
669 Program. CRG acknowledge the support of the Spanish Ministry of Science, Innovation, and
670 Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA
671 Programme/Generalitat de Catalunya.

672

673 LM is funded by a Juan de la Cierva-Incorporación fellowship (IJC2018-035394-I) awarded by the
674 Spanish Ministerio de Economía, Industria y Competitividad. MC holds a Miguel Servet fellowship
675 (MS16/00128) funded by Instituto de Salud Carlos III and co-funded by European Social Fund
676 "Investing in your future".

677

678 10. Data Availability Statement

679

680 Summarized results can be found at <https://helixomics.isglobal.org/> (THIS WILL BE DONE
681 UPON ACCEPTANCE OF THE MANUSCRIPT). The raw data supporting the current study are

682 available from the corresponding author on request subject to ethical and legislative review. The
683 “HELIX Data External Data Request Procedures” are available with the data inventory in this
684 website: <http://www.projecthelix.eu/data-inventory>.

685

686

687 **11. References**

688

689 Bhattacharyya, M., Basu, S., Dhar, R., Dutta, T.K., 2022. Phthalate hydrolase: distribution,
690 diversity and molecular evolution. *Environ. Microbiol. Rep.* 14, 333–346.

691 <https://doi.org/10.1111/1758-2229.13028>

692 Braun, J.M., 2017. Early-life exposure to EDCs: role in childhood obesity and
693 neurodevelopment. *Nat. Rev. Endocrinol.* 13, 161–173.

694 <https://doi.org/10.1038/nrendo.2016.186>

695 Bruhn, O., Cascorbi, I., 2014. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2
696 and ABCC3 and their impact on drug bioavailability and clinical relevance. *Expert Opin.*

697 *Drug Metab. Toxicol.* 10, 1337–1354. <https://doi.org/10.1517/17425255.2014.952630>

698 Casale, J., Rice, A.S., 2023. Phthalates Toxicity, StatPearls Treasure Island (FL). StatPearls
699 Publishing.

700 Ceauranu, S., Ciorsac, A., Ostafe, V., Isvoran, A., 2023. Evaluation of the Toxicity Potential of
701 the Metabolites of Di-Isononyl Phthalate and of Their Interactions with Members of Family
702 1 of Sulfotransferases - A Computational Study. *Molecules* 28, 6748–65.

703 <https://doi.org/10.3390/molecules28186748/S1>

704 Choi, K., Joo, H., Campbell, J.L., Clewell, R.A., Andersen, M.E., Clewell, H.J., 2012. In vitro
705 metabolism of di(2-ethylhexyl) phthalate (DEHP) by various tissues and cytochrome P450s
706 of human and rat. *Toxicol. Vit.* 26, 315–22. <https://doi.org/10.1016/j.tiv.2011.12.002>

707 Conrad, D.F., Pinto, D., Redon, R., Feuk, L., Gokcumen, O., Zhang, Y., Aerts, J., Andrews,
708 T.D., Barnes, C., Campbell, P., Fitzgerald, T., Hu, M., Ihm, C.H., Kristiansson, K.,

709 MacArthur, D.G., MacDonald, J.R., Onyiah, I., Pang, A.W.C., Robson, S., Stirrups, K.,
710 Valsesia, A., Walter, K., Wei, J., Tyler-Smith, C., Carter, N.P., Lee, C., Scherer, S.W.,

711 Hurles, M.E., 2010. Origins and functional impact of copy number variation in the human
712 genome. *Nature* 464, 704–712. <https://doi.org/10.1038/nature08516>

713 D. Turner, S., 2018. qqman: an R package for visualizing GWAS results using Q-Q and

714 manhattan plots. *J. Open Source Softw.* 3, 731–732. <https://doi.org/10.21105/joss.00731>

715 Da Silva, V., Ramos, M., Groenen, M., Crooijmans, R., Johansson, A., Regitano, L., Coutinho,
716 L., Zimmer, R., Waldron, L., Geistlinger, L., 2020. CNVRanger: association analysis of

717 CNVs with gene expression and quantitative phenotypes. *Bioinformatics* 36, 972–973.

718 <https://doi.org/10.1093/bioinformatics/btz632>

719 Deeley, R.G., Westlake, C., Cole, S.P.C., 2006. Transmembrane transport of endo- and
720 xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. *Physiol.*

721 *Rev.* 86, 849–899. <https://doi.org/10.1152/PHYSREV.00035.2005>

722 Domínguez-Romero, E., Scherlinger, M., 2019. A review of phthalate pharmacokinetics in

723 human and rat: what factors drive phthalate distribution and partitioning? *Drug Metab. Rev.*

724 51, 314–329. <https://doi.org/10.1080/03602532.2019.1620762>

725 Durinck, S., Spellman, P.T., Birney, E., Huber, W., 2009. Mapping identifiers for the integration
726 of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* 4, 1184–1191.

727 <https://doi.org/10.1038/NPROT.2009.97>

- 728 Feofanova, E. V., Chen, H., Dai, Y., Jia, P., Grove, M.L., Morrison, A.C., Qi, Q., Daviglius, M.,
729 Cai, J., North, K.E., Laurie, C.C., Kaplan, R.C., Boerwinkle, E., Yu, B., 2020. A Genome-
730 wide Association Study Discovers 46 Loci of the Human Metabolome in the Hispanic
731 Community Health Study/Study of Latinos. *Am. J. Hum. Genet.* 107, 849–863.
732 <https://doi.org/10.1016/J.AJHG.2020.09.003>
- 733 Frederiksen, H., Skakkebaek, N.E., Andersson, A.M., 2007. Metabolism of phthalates in humans.
734 *Mol. Nutr. Food Res.* 51, 899–911. <https://doi.org/10.1002/mnfr.200600243>
- 735 Gan, B., Yu, L., Yang, H., Jiao, H., Pang, B., Chen, Y., Wang, C., Lv, R., Hu, H., Cao, Z., Ren,
736 R., 2023. Mechanism of agonist-induced activation of the human itch receptor MRGPRX1.
737 *PLOS Biol.* 21, e3001975. <https://doi.org/10.1371/JOURNAL.PBIO.3001975>
- 738 González, J.R., Armengol, L., Solé, X., Guinó, E., Mercader, J.M., Estivill, X., Moreno, V.,
739 2007. SNPassoc: An R package to perform whole genome association studies.
740 *Bioinformatics* 23, 644–645. <https://doi.org/10.1093/bioinformatics/btm025>
- 741 Haug, L.S., Sakhi, A.K., Cequier, E., Casas, M., Maitre, L., Basagana, X., Andrusaityte, S.,
742 Chalkiadaki, G., Chatzi, L., Coen, M., de Bont, J., Dedele, A., Ferrand, J., Grazuleviciene,
743 R., Gonzalez, J.R., Gutzkow, K.B., Keun, H., McEachan, R., Meltzer, H.M., Petraviciene,
744 I., Robinson, O., Saulnier, P.-J., Slama, R., Sunyer, J., Urquiza, J., Vafeiadi, M., Wright, J.,
745 Vrijheid, M., Thomsen, C., 2018. In-utero and childhood chemical exposome in six
746 European mother-child cohorts. *Environ. Int.* 121, 751–763.
747 <https://doi.org/10.1016/J.ENVINT.2018.09.056>
- 748 Hollis-Moffatt, J.E., Phipps-Green, A.J., Chapman, B., Jones, G.T., van Rij, A., Gow, P.J.,
749 Harrison, A.A., Highton, J., Jones, P.B., Montgomery, G.W., Stamp, L.K., Dalbeth, N.,
750 Merriman, T.R., 2012. The renal urate transporter SLC17A1 locus: Confirmation of
751 association with gout. *Arthritis Res. Ther.* 14, R92. <https://doi.org/10.1186/ar3816>
- 752 Huang, H., Lan, B. Di, Zhang, Y.J., Fan, X.J., Hu, M.C., Qin, G.Q., Wang, F.G., Wu, Y., Zheng,
753 T., Liu, J.H., 2022. Inhibition of Human Sulfotransferases by Phthalate Monoesters. *Front.*
754 *Endocrinol. (Lausanne).* 13, 1–9. <https://doi.org/10.3389/fendo.2022.868105>
- 755 Kim, S.H., Park, M.J., 2014. Phthalate exposure and childhood obesity. *Ann. Pediatr.*
756 *Endocrinol. Metab.* 19, 69–75. <https://doi.org/10.6065/APEM.2014.19.2.69>
- 757 Klaassen, C.D., Aleksunes, L.M., 2010. Xenobiotic, bile acid, and cholesterol transporters:
758 Function and regulation. *Pharmacol. Rev.* 62, 1–96. <https://doi.org/10.1124/pr.109.002014>
- 759 Kwan, W.S., Roy, V.A.L., Yu, K.N., 2021. Review on Toxic Effects of Di(2-ethylhexyl)
760 Phthalate on Zebrafish Embryos. *Toxics* 9, 193–215.
761 <https://doi.org/10.3390/TOXICS9080193>
- 762 Lee, D.W., Lim, H.M., Lee, J.Y., Min, K.B., Shin, C.H., Lee, Y.A., Hong, Y.C., 2022. Prenatal
763 exposure to phthalate and decreased body mass index of children: a systematic review and
764 meta-analysis. *Sci. Reports* 2022 12, 1–18. <https://doi.org/10.1038/s41598-022-13154-9>
- 765 Lee, S., Lee, H.A., Park, B., Han, H., Hong, Y.S., Ha, E.H., Park, H., 2023. Prospective
766 association between phthalate exposure in childhood and liver function in adolescence: the
767 Ewha Birth and Growth Cohort Study. *Environ. Heal. A Glob. Access Sci. Source* 22, 1–12.
768 <https://doi.org/10.1186/S12940-022-00953-W/FIGURES/2>
- 769 Liu, X., 2019. SLC Family Transporters. *Adv. Exp. Med. Biol.* 1141, 101–202.
770 https://doi.org/10.1007/978-981-13-7647-4_3
- 771 Maitre, L., de Bont, J., Casas, M., Robinson, O., Aasvang, G.M., Agier, L., Andrusaitytė, S.,
772 Ballester, F., Basagaña, X., Borràs, E., Brochot, C., Bustamante, M., Carracedo, A., de
773 Castro, M., Dedele, A., Donaire-Gonzalez, D., Estivill, X., Evandt, J., Fossati, S., Giorgis-

- 774 Allemand, L., R Gonzalez, J., Granum, B., Grazuleviciene, R., Bjerve Gützkow, K.,
775 Småstuen Haug, L., Hernandez-Ferrer, C., Heude, B., Ibarluzea, J., Julvez, J., Karachaliou,
776 M., Keun, H.C., Hjertager Krog, N., Lau, C.-H.E., Leventakou, V., Lyon-Caen, S.,
777 Manzano, C., Mason, D., McEachan, R., Meltzer, H.M., Petraviciene, I., Quentin, J.,
778 Roumeliotaki, T., Sabido, E., Saulnier, P.-J., Siskos, A.P., Siroux, V., Sunyer, J., Tamayo,
779 I., Urquiza, J., Vafeiadi, M., van Gent, D., Vives-Usano, M., Waiblinger, D., Warembourg,
780 C., Chatzi, L., Coen, M., van den Hazel, P., Nieuwenhuijsen, M.J., Slama, R., Thomsen, C.,
781 Wright, J., Vrijheid, M., 2018. Human Early Life Exposome (HELIX) study: a European
782 population-based exposome cohort. *BMJ Open* 8, e021311.
783 <https://doi.org/10.1136/bmjopen-2017-021311>
- 784 Maywald, M.L., Picciotto, C., Lepa, C., Bertgen, L., Yousaf, F.S., Ricker, A., Klingauf, J.,
785 Krahn, M.P., Pavenstädt, H., George, B., 2022. Rap1 Activity Is Essential for Focal
786 Adhesion and Slit Diaphragm Integrity. *Front. Cell Dev. Biol.* 10, 790365, 1–14.
787 <https://doi.org/10.3389/FCELL.2022.790365/BIBTEX>
- 788 Nurtdinov, R., Guigó, R., n.d. EPIraction - an atlas of candidate enhancer-gene interactions in
789 human tissues and cell lines. [Manuscript in preparation].
- 790 O'Brien, K.M., Upson, K., Buckley, J.P., 2017. Lipid and Creatinine Adjustment to Evaluate
791 Health Effects of Environmental Exposures. *Curr. Environ. Heal. reports* 4, 44–50.
792 <https://doi.org/10.1007/S40572-017-0122-7/FIGURES/2>
- 793 Pazoki, R., Vujkovic, M., Elliott, J., Evangelou, E., Gill, D., Ghanbari, M., van der Most, P.J.,
794 Pinto, R.C., Wielscher, M., Farlik, M., Zuber, V., de Knecht, R.J., Snieder, H., Uitterlinden,
795 A.G., Boezen, H.M., Franke, L., van der Harst, P., Navis, G., Rots, M., Swertz, M.,
796 Wolffenbuttel, B.H.R., Wijmenga, C., Lynch, J.A., Jiang, X., Said, S., Kaplan, D.E., Lee,
797 K.M., Serper, M., Carr, R.M., Tsao, P.S., Atkinson, S.R., Dehghan, A., Tzoulaki, I., Ikram,
798 M.A., Herzig, K.H., Järvelin, M.R., Alizadeh, B.Z., O'Donnell, C.J., Saleheen, D., Voight,
799 B.F., Chang, K.M., Thursz, M.R., Elliott, P., Ballas, Z.K., Bhushan, S., Boyko, E.J., Cohen,
800 D.M., Concato, J., Aslan, M., Zhao, H., Constans, J.I., Dellitalia, L.J., Fayad, J.M.,
801 Fernando, R.S., Florez, H.J., Gaddy, M.A., Gappy, S.S., Gibson, G., Godschalk, M., Greco,
802 J.A., Gupta, S., Gutierrez, S., Hammer, K.D., Hamner, M.B., Harley, J.B., Hung, A.M.,
803 Huq, M., Hurley, R.A., Iruvanti, P.R., Ivins, D.J., Jacono, F.J., Jhala, D.N., Kaminsky, L.S.,
804 Klein, J.B., Liangpunsakul, S., Lichy, J.H., Moser, J., Huang, G.D., Muralidhar, S.,
805 Mastorides, S.M., Mathew, R.O., Mattocks, K.M., McArdle, R., Meyer, P.N., Meyer, L.J.,
806 Moorman, J.P., Morgan, T.R., Murdoch, M., Okusaga, O.O., Oursler, K.A.K., Ratcliffe,
807 N.R., Rauchman, M.I., Robey, R.B., Ross, G.W., Servatius, R.J., Sharma, S.C., Sherman,
808 S.E., Sonel, E., Sriram, P., Stapley, T., Striker, R.T., Tandon, N., Villareal, G., Wallbom,
809 A.S., Wells, J.M., Whittle, J.C., Whooley, M.A., Wilson, P.W., Sun, Y. V., Xu, J., Yeh,
810 S.S., Connor, T., Argyres, D.P., Hauser, E.R., Beckham, J.C., Stephens, B., Aguayo, S.M.,
811 Ahuja, S.K., Pyarajan, S., Cho, K., Gaziano, J.M., Kinlay, S., Nguyen, X.M.T., Brewer, J.
812 V., Brophy, M.T., Do, N. V., Humphries, D.E., Selva, L.E., Shayan, S., Whitbourne, S.B.,
813 Breeling, J.L., Romero, J.P.C., Ramoni, R.B., 2021. Genetic analysis in European ancestry
814 individuals identifies 517 loci associated with liver enzymes. *Nat. Commun.* 12, 2579, 1–
815 12. <https://doi.org/10.1038/S41467-021-22338-2>
- 816 Pedersen, B.S., Quinlan, A.R., 2017. Who's Who? Detecting and Resolving Sample Anomalies
817 in Human DNA Sequencing Studies with Peddy. *Am. J. Hum. Genet.* 100, 406–413.
818 <https://doi.org/10.1016/j.ajhg.2017.01.017>
- 819 Philippat, C., Calafat, A.M., 2021. Comparison of strategies to efficiently combine repeated

- 820 urine samples in biomarker-based studies. *Environ. Res.* 192, 110275, 1–9.
821 <https://doi.org/10.1016/J.ENVRES.2020.110275>
- 822 Pinto, N., Eileen Dolan, M., 2011. Clinically Relevant Genetic Variations in Drug Metabolizing
823 Enzymes. *Curr. Drug Metab.* 12, 487–497. <https://doi.org/10.2174/138920011795495321>
- 824 Praveena, S.M., Teh, S.W., Rajendran, R.K., Kannan, N., Lin, C.C., Abdullah, R., Kumar, S.,
825 2018. Recent updates on phthalate exposure and human health: a special focus on liver
826 toxicity and stem cell regeneration. *Environ. Sci. Pollut. Res.* 25, 11333–11342.
827 <https://doi.org/10.1007/s11356-018-1652-8>
- 828 Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar,
829 P., de Bakker, P.I., Daly, M.J., Sham, P.C., 2007. PLINK: a tool set for whole-genome
830 association and population-based linkage analyses. *Am J Hum Genet* 81, 559–575.
- 831 Ramírez-Cosmes, A., Reyes-Jiménez, E., Zertuche-Martínez, C., Hernández-Hernández, C.A.,
832 García-Román, R., Romero-Díaz, R.I., Manuel-Martínez, A.E., Elizarrarás-Rivas, J.,
833 Vásquez-Garzón, V.R., 2021. The implications of ABCC3 in cancer drug resistance: can we
834 use it as a therapeutic target? *Am. J. Cancer Res.* 11, 4127–40.
- 835 Sakhi, A.K., Sabaredzovic, A., Cequier, E., Thomsen, C., 2017. Phthalate metabolites in
836 Norwegian mothers and children: Levels, diurnal variation and use of personal care
837 products. *Sci. Total Environ.* 599–600, 1984–1992.
838 <https://doi.org/10.1016/J.SCITOTENV.2017.05.109>
- 839 Schlosser, P., Li, Y., Sekula, P., Raffler, J., Grundner-Culemann, F., Pietzner, M., Cheng, Y.,
840 Wuttke, M., Steinbrenner, I., Schultheiss, U.T., Kotsis, F., Kacprowski, T., Forer, L.,
841 Hausknecht, B., Ekici, A.B., Nauck, M., Völker, U., Walz, G., Oefner, P.J., Kronenberg, F.,
842 Mohny, R.P., Köttgen, M., Suhre, K., Eckardt, K.U., Kastenmüller, G., Köttgen, A., 2020.
843 Genetic studies of urinary metabolites illuminate mechanisms of detoxification and
844 excretion in humans. *Nat. Genet.* 52, 167–176. <https://doi.org/10.1038/S41588-019-0567-8>
- 845 Stajniko, A., Runkel, A.A., Kosjek, T., Snoj Tratnik, J., Mazej, D., Falnoga, I., Horvat, M., 2022.
846 Assessment of susceptibility to phthalate and DINCH exposure through CYP and UGT
847 single nucleotide polymorphisms. *Environ. Int.* 159, 107046, 1–13.
848 <https://doi.org/10.1016/j.envint.2021.107046>
- 849 Stanzick, K.J., Li, Y., Schlosser, P., Gorski, M., Wuttke, M., Thomas, L.F., Rasheed, H., Rowan,
850 B.X., Graham, S.E., Vanderweff, B.R., Patil, S.B., Robinson-Cohen, C., Gaziano, J.M.,
851 O'Donnell, C.J., Willer, C.J., Hallan, S., Åsvold, B.O., Gessner, A., Hung, A.M., Pattaro,
852 C., Köttgen, A., Stark, K.J., Heid, I.M., Winkler, T.W., 2021. Discovery and prioritization
853 of variants and genes for kidney function in >1.2 million individuals. *Nat. Commun.* 12,
854 4350, 1–17. <https://doi.org/10.1038/S41467-021-24491-0>
- 855 Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P.,
856 Ranganath, V., Kumanduri, V., McLaren, W., Holm, L., Lindh, J., Rane, A., Wadelius, M.,
857 Deloukas, P., 2009. A genome-wide association study confirms VKORC1, CYP2C9, and
858 CYP4F2 as principal genetic determinants of warfarin dose. *PLoS Genet.* 5, e1000433, 1–9.
859 <https://doi.org/10.1371/JOURNAL.PGEN.1000433>
- 860 Torres, A.M., Dnyanmote, A. V., Granados, J.C., Nigam, S.K., 2021. Renal and non-renal
861 response of ABC and SLC transporters in chronic kidney disease. *Expert Opin. Drug*
862 *Metab. Toxicol.* 17, 515–542. <https://doi.org/10.1080/17425255.2021.1899159>
- 863 Visscher, P.M., Wray, N.R., Zhang, Q., Sklar, P., McCarthy, M.I., Brown, M.A., Yang, J., 2017.
864 10 Years of GWAS Discovery: Biology, Function, and Translation. *Am. J. Hum. Genet.*
865 101, 5–22. <https://doi.org/10.1016/j.ajhg.2017.06.005>

- 866 Vogel, N., Schmidt, P., Lange, R., Gerofke, A., Sakhi, A.K., Haug, L.S., Jensen, T.K.,
867 Frederiksen, H., Szigeti, T., Csákó, Z., Murinova, L.P., Sidlovska, M., Janasik, B.,
868 Wasowicz, W., Tratnik, J.S., Mazej, D., Gabriel, C., Karakitsios, S., Barbone, F., Rosolen,
869 V., Rambaud, L., Riou, M., Murawski, A., Leseman, D., Koppen, G., Covaci, A., Lignell,
870 S., Lindroos, A.K., Zvonar, M., Andryskova, L., Fabelova, L., Richterova, D., Horvat, M.,
871 Kosjek, T., Sarigiannis, D., Maroulis, M., Pedraza-Diaz, S., Cañas, A., Verheyen, V.J.,
872 Bastiaensen, M., Gilles, L., Schoeters, G., Esteban-López, M., Castaño, A., Govarts, E.,
873 Koch, H.M., Kolossa-Gehring, M., 2023. Current exposure to phthalates and DINCH in
874 European children and adolescents – Results from the HBM4EU Aligned Studies 2014 to
875 2021. *Int. J. Hyg. Environ. Health* 249, 114101, 1–11.
876 <https://doi.org/10.1016/J.IJHEH.2022.114101>
- 877 Wang, I.J., Karmaus, W.J.J., 2017. Oxidative Stress-Related Genetic Variants May Modify
878 Associations of Phthalate Exposures with Asthma. *Int. J. Environ. Res. Public Health* 14,
879 162–75. <https://doi.org/10.3390/IJERPH14020162>
- 880 Wang, K., Li, M., Hadley, D., Liu, R., Glessner, J., Grant, S.F.A., Hakonarson, H., Bucan, M.,
881 2007. PennCNV: An integrated hidden Markov model designed for high-resolution copy
882 number variation detection in whole-genome SNP genotyping data. *Genome Res.* 17, 1665–
883 1674. <https://doi.org/10.1101/GR.6861907>
- 884 Wang, X.X., Wang, D., Luo, Y., Myakala, K., Dobrinskikh, E., Rosenberg, A.Z., Levi, J., Kopp,
885 J.B., Field, A., Hill, A., Lucia, S., Qiu, L., Jiang, T., Peng, Y., Orlicky, D., Garcia, G.,
886 Herman-Edelstein, M., D’Agati, V., Henriksen, K., Adorini, L., Pruzanski, M., Xie, C.,
887 Krausz, K.W., Gonzalez, F.J., Ranjit, S., Dvornikov, A., Gratton, E., Levi, M., 2018.
888 FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. *J.*
889 *Am. Soc. Nephrol.* 29, 118–137. <https://doi.org/10.1681/ASN.2017020222>
- 890 Wang, Y., Zhu, H., Kannan, K., 2019. A Review of Biomonitoring of Phthalate Exposures.
891 *Toxics* 7, 1–28. <https://doi.org/10.3390/TOXICS7020021>
- 892 Watanabe, K., Taskesen, E., Van Bochoven, A., Posthuma, D., 2017. Functional mapping and
893 annotation of genetic associations with FUMA. *Nat. Commun.* 8, 1826–36.
894 <https://doi.org/10.1038/s41467-017-01261-5>
- 895 Wickham, H., 2016. *ggplot2: Elegant Graphics for Data Analysis, Use R!* Springer Cham.
896 <https://doi.org/10.1007/978-3-319-24277-4>
- 897 Williams, M.J., Wiemerslage, L., Gohel, P., Kheder, S., Kothegala, L. V., Schiöth, H.B., 2016.
898 Dibutyl Phthalate Exposure Disrupts Evolutionarily Conserved Insulin and Glucagon-Like
899 Signaling in *Drosophila* Males. *Endocrinology* 157, 2309–2321.
900 <https://doi.org/10.1210/EN.2015-2006>
- 901 Zhu, B., Cao, A., Li, J., Young, J., Wong, J., Ashraf, S., Bierzynska, A., Menon, M.C., Hou, S.,
902 Sawyers, C., Campbell, K.N., Saleem, M.A., He, J.C., Hildebrandt, F., D’Agati, V.D., Peng,
903 W., Kaufman, L., 2019. Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to
904 podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2.
905 *Kidney Int.* 96, 642–55. <https://doi.org/10.1016/J.KINT.2019.03.016>
906
907
908
909

910 **Tables**
911

Table 1. Descriptive of the study population

For continuous variables mean and SD are shown, while for categorical variables the sample size and its percentage % are reported. LMW: low molecular weight. HMW: high molecular weight. N=1,044.

Variable	N (%), Mean (SD)	N missing
Cohort		
BiB (UK)	90 (8.62%)	0
EDEN (France)	135 (12.93%)	0
KAUNAS (Lithuania)	196 (18.77%)	0
MoBa (Norway)	239 (22.89%)	0
RHEA (Greece)	186 (17.82%)	0
INMA (Spain)	198 (18.97%)	0
Child's sex		
Females	473 (45.31%)	0
Males	571 (54.69%)	0
Child's age (years)	7.96 (1.54)	0
Child's obesity		
Normal	830 (79.50%)	0
Overweight	155 (14.85%)	0
Obese	59 (5.66%)	0
Maternal education		
Primary	115 (11.02%)	0
Secondary	353 (33.81%)	0
University or higher	550 (52.68%)	0
Urinary creatinine levels (g per ml of urine)	1.004 (0.350)	0
Urinary LMW phthalate levels (µg per g of creatinine)		
MBzP	8.85 (16.14)	0
MEP	77.32 (184.98)	0
MiBP	57.48 (60.29)	0
MnBP	33.78 (37.75)	0
Urinary HMW phthalate levels (µg per g of creatinine)		
MEHP	4.67 (11.09)	34
MECPP*	53.56 (131.78)	0
MEHHP*	31.20 (84.53)	3
MEOHP*	18.80 (46.17)	1
oh-MiNP	9.09 (16.20)	0
oxo-MiNP**	5.62 (15.82)	0

*Metabolites of MEHP, **Metabolite of oh-MiNP

912
913
914

915

Table 2. Summary of the results of the single-trait GWAS of phthalate levels and their ratios

A locus is defined as a region of 1 Mb with SNPs with similar effect size on the trait

Suggestive statistical significance is set at p-value <1E-05

Class	Phthalate	N	Lambda	N genome-wide sig. SNPs	N genome-wide sig. loci	N suggestive sig. SNPs	N suggestive sig. loci	Minimum p-value
LMW	MBzP	1044	0.996	1	1	30	6	4.28E-08
LMW	MEP	1044	0.997	0	0	21	8	9.37E-07
LMW	MiBP	1044	1.007	0	0	62	7	1.80E-07
LMW	MnBP	1044	1.008	0	0	58	10	4.98E-07
HMW	MEHP	1010	1.000	0	0	25	11	1.39E-06
HMW	MEHHP	1041	1.018	0	0	128	15	6.17E-08
HMW	MECPP	1044	1.021	0	0	505	15	1.36E-07
HMW	MEOHP	1043	1.018	0	0	67	12	2.66E-07
HMW	oh-MiNP	1044	1.013	0	0	32	12	2.23E-06
HMW	oxo-MiNP	1044	0.987	0	0	17	5	1.33E-06
HMW ratio	MEHHP_MEHP	1009	0.986	0	0	83	11	3.62E-07
HMW ratio	MECPP_MEHP	1010	0.987	369	1	563	11	2.10E-20
	MECPP_MEHH							
HMW ratio	P	1041	1.017	774	2	1091	11	1.45E-63
HMW ratio	MEOHP_MEHP	1009	0.986	0	0	417	12	5.72E-07
	MEOHP_MEHH							
HMW ratio	P	1040	1.006	186	1	307	11	2.81E-14
HMW ratio	oxo-MiNP_oh-MiNP	1044	0.999	2	1	66	7	4.15E-08
	Total*			1332	6	3472	164	
	Total**					2140	158	
	Total unique*				4		117	
	Total unique**						113	

*including genome-wide significant SNPs

**without including genome-wide significant SNPs

916

917

Table 3. Selected loci associated with phthalate levels and/or ratios, ordered by p-value

A locus is defined as a region of 1Mb with SNPs with similar R2 on the trait.

The lead SNPs is the SNP with the lowest p-value in the locus. If more than one, then one is arbitrary selected and shown.


* According to the notation for the lead SNPs of the single-lead GWAS

** In brackets suggestive associations

*** After a notation with FUMA, thus including SNPs not genotyped but in linkage disequilibrium

Locus*	Phthalate**	Chr	Pos_bkg	Lead SNP	Non-effect allele	Effect allele	Beta	Standard error	P-value	N SNPs in locus**	Number independent SNPs	Nearest gene to lead SNP	Relative gene position	Other genes in locus	eQTLs	Gene-enhancer interactions	GWAS catalog	Candidate gene function	
1	(MECPP_MEHPP; MECP; MEHP; MEQHP_MEHP; MECP); (MEQHP_MEHP)	10	96719845	rs74494115	G	T	-0.3087	0.0171	1.45E-63	1132	26	CYP2C9	Intronic	MYOF; FRA19A1; LGI1; SLC35G1; PCE1; NOC3L; TBC1D12; HELLS; CYP2C18; CYP2C19; CYP2C8; C10orf129; PDLIM1; SORBS1; ALDH18A1; TCTN3; ENTPD1; CCNJ; M2; others	Several but not liver or kidney (MYOF; FRA19A1; LGI1; SLC35G1; NOC3L; TBC1D12; HELLS; CYP2C18; CYP2C19; CYP2C8; C10orf129; PDLIM1; SORBS1); kidney (NOC3L; TBC1D12; HELLS; CYP2C18; CYP2C9; CYP2C8; PDLIM1; SORBS1; ALDH18A1; TCTN3; ENTPD1; M2 (in trans))	Liver (LGI1; SLC35G1; PCE1; NOC3L; TBC1D12; HELLS; CYP2C18; CYP2C19; CYP2C8; C10orf129; PDLIM1; SORBS1); kidney (NOC3L; TBC1D12; HELLS; CYP2C18; CYP2C9; CYP2C8; PDLIM1; SORBS1; ALDH18A1; TCTN3; ENTPD1; CCNJ)	Serum/plasma metabolite levels; liver enzyme levels (alkaline phosphatase); drug response/metabolization (ex. warfarin); gout	Cytochrome P450 monooxygenases: Catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. CYP2C8 (xenobiotics); CYP2C9 (xenobiotics); CYP2C18 (unknown) and CYP2C19 (xenobiotics) // SLC35G1 (Solute Carrier Family 35 Member G1): Drug/metabolite transporter protein.	
2	(MECPP_MEHPP; MECP); (MEQHP_MEHP); (MEHP_MEHP); (oh-MNP)	6	25809716	rs1359232	C	A	-0.1335	0.0156	4.58E-17	462	12	SCL17A1	Intronic	SCGN; HIST1H cluster; SCL17A2; SCL17A3; SCL17A4; TRIM38; GPX5; GPX8 and others	Liver (SCL17A1; SCL17A3; SCL17A4); kidney (SCL17A3); others	Liver (SCGN; SCL17A1; SCL17A2; SCL17A3; SCL17A4; HIST1H cluster and others); kidney (SCL17A1; SCL17A3; SCL17A3)	Urate levels; urinary metabolite levels; serum/plasma metabolite levels; gout; diastolic blood pressure; hematocrit; estimated glomerular filtration rate (creatinine)	Solute Carrier Family 17 Members: Facilitate transport of molecules across membranes. SLC17A4 (phosphate excretion); SLC17A1 and SLC17A3 (urate excretion); SLC17A2 (sialic acid transport) // Glutathione Peroxidase Members: GPX5 and GPX8 (reduction of hydrogen peroxide, organic hydroperoxides and lipid hydroperoxides)	
3	(oh-MNP; oh-MNP; MEQHP_MEHP)	3	34882408	rs80064213	T	C	0.3307	0.0598	4.15E-08	59	2	FECHP1	Intergenic	PDCD6IP; ARPP21; STAC; DCLK3	None	None	None	Body mass index; breast cancer	STAC (SH3 And Cysteine Rich Domain): Predicted to enable transmembrane transporter binding activity.
4	MB2P	9	134523638	rs138702233	C	T	0.3938	0.0713	4.29E-08	40	2	RAPGEF1	Intronic	AIF1; NUP214; FAM78A; PPAPDC3; PRRC2B; POMT1; UCK1; MED27; NTNG2; SETX; TTF1; C9orf171; DDX31; GTF3C4; AK8; C9orf8; TSC1; GF1B	Several but not liver or kidney (AIF1; PPAPDC3; PRRC2B; POMT1; RAPGEF1)	Liver (AIF1; NUP214; POMT1; UCK1; RAPGEF1); kidney (FAM78A; POMT1; UCK1; RAPGEF1; MED27; NTNG2)	None	Human guanine nucleotide exchange factor. It is related to Nephrotic Syndrome, Type 7 and Membranoproliferative Glomerulonephritis.	
5	(MEHP); (MEQHP); (MECP)	2	107637715	rs77376475	A	G	0.3092	0.0567	6.17E-08	2	1	AC005040.3	Intergenic	SULT1C3; ST6GAL2	Dorsolateral Prefrontal Cortex (ST6GAL2)	None	None	None	SULT1C3 (Sulfotransferase Family 1C Member 3): Sulfate conjugation of endogenous compounds and xenobiotics.
6	(MEQHP_MEHP)	1	242361140	rs10926644	T	C	-0.0522	0.0097	8.43E-08	31	2	PLD5	Intronic	CHRM3; FH; KMO; CHML; WDR64; EXO1; MAP1L3C; CEP170; SDCCAG8; ZBTB18; ADSS; C10orf101	Brain (PLD5)	None	Response to cytidine analogues (cytosine arabinoside); total PHF-tau	FH (Fumarate Hydratase): Enzyme of the Krebs cycle that catalyzes the formation of L-malate from fumarate. // KMO (Kynurenine 3-Monooxygenase): Catalyzes the hydroxylation of L-tryptophan metabolite, L-kynurenine, to form L-3-hydroxykynurenine. // PLD5 (Phospholipase D Family Member 5): Predicted to enable catalytic activity. // ADSS (Adenylosuccinate Synthase 2): Catalyzes the first committed step in the conversion of inosine monophosphate to adenosine monophosphate.	
7	(MEQHP); (MEHP); (MECP); (MECP_MEHP); (MEHP_MEHP)	18	76807781	rs176807781:G:A	A	G	0.1458	0.0288	5.00E-07	116	2	SALL3	Intergenic	GALR1; HSBP1L1; PARD6G-AS1; NFATC1; ATP9B	Several but not liver or kidney (GALR1; HSBP1L1; PARD6G-AS1; NFATC1; ATP9B)	Kidney and liver (ATP9B)	Frontotemporal dementia	ATP9B (ATPase Phospholipid Transporting 9B - Putative): Predicted to enable ATPase-coupled intramembrane lipid transporter activity.	
8	(MECPP_MEHP)	19	49250239	rs1949250239:C:T	T	C	-0.0765	0.0161	2.42E-06	104	1	IZUMO1	Intergenic	SLC8A2; PLA2G4C; CARD8; SUL12B1; FAM83E; SPAC4; RPL18; SPHK2; DBP; CA11; NTN5; FUT2; MAMSTR; RASIP1; FUT1; FGF21; BCAT2; HSD17B14; BAX; FTL; GYS1; RUVBL2; LHB; others	Several tissues (PLA2G4C; CARD8; SUL12B1; FAM83E; RPL18; SPHK2; DBP; CA11; NTN5; FUT2; MAMSTR; RASIP1; FUT1; FGF21; BCAT2; HSD17B14; RUVBL2)	Liver (RPL18; SPHK2; DBP; CA11; MAMSTR; RASIP1; FUT1; FGF21; HSD17B14; BCAT2); kidney (FAM83E; RPL18; SPHK2; DBP; CA11; NTN5; FUT2; MAMSTR; RASIP1; FUT1; FGF21; HSD17B14; FTL; GYS1; RUVBL2; LHB)	Paired metabolites in plasma and urine; plasma proteins; intestinal-type alkaline phosphatase levels; liver enzyme levels (gamma-glutamyl transferase); urinary albumin-to-creatinine ratio; urinary metabolites, aspartate aminotransferase levels; others	HSD17B14 (Hydroxysteroid 17-Beta Dehydrogenase 14): Metabolism of steroids and also of other substrates, such as fatty acids, prostaglandins, and xenobiotics. // SLC8A2 (Solute Carrier Family 8 Member A2): Predicted to enable calcium/cation antiporter activity. Involved in regulation of postsynaptic cytosolic calcium ion concentration and calcium/sodium antiporter activity. // SUL12B1 (Sulfotransferase Family 2B Member 1): Sulfate conjugation of many hormones, neurotransmitters, drugs, and xenobiotic compounds	
9	(MEQHP_MEHP)	17	48751114	rs72837555	C	T	-0.1472	0.0319	4.54E-06	12	1	ABCC3	Intronic	CHAD; RSAD1; MYCBPAP; EPN3; SPATA20; CACNA1G; ANKRD40; LUC7L3; WFIKKN2; TOB1; NME1; NME2	Several tissues but not liver or kidney (SPATA20; ABCC3; ANKRD40; WFIKKN2; NME1-NME2)	Liver (ABCC3; ANKRD40; LUC7L3)	Serum/plasma metabolite levels	ABCC3 (ATP Binding Cassette Subfamily C Member 3): Member of the superfamily of ATP-binding cassette (ABC) transporters of molecules across extra- and intra-cellular membranes. Involved in multi-drug resistance.	
10	(MEP)	19	41148101	rs2561564	T	G	-0.3124	0.0684	5.61E-06	2	1	LTP4	Intergenic	AKT2; C19orf47; PLD3; SERTAD1; SERTAD3; SHKBP1; NUMBL; ADCK4; ITPKC; C19orf54; SNRPA; MIA; MIA-RAB4B; RAB4B; RAB4B-EGLN2; EGLN2; CYP2A6; CYP2B6; CYP2A13; CYP2S1; others	Several but not liver or kidney (SERTAD1; SHKBP1; LTP4; NUMBL; ADCK4; ITPKC; C19orf54; RAB4B; RAB4B-EGLN2; EGLN2)	Liver (CYP2A13)	None	Cytochrome P450 monooxygenases: Catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. CYP2A6 (xenobiotics); CYP2B6 (xenobiotics); CYP2A13 (a major nitrosamine specific to tobacco); and CYP2S1 (carcinogens).	
11	(MEHP)	4	70619038	rs1394032	G	C	0.18421	0.041	7.6E-06	46	1	SULT1B1	Intronic	TM6RSS118N; TPRS118; UGT1B11; UGT2A1; UGT2A2; UGT2A2; SULT1B1; SULT1E1; CSN1S1; ODM; FDCSP; CSN3; PROL1; AMTN	Several tissues (UGT2B11; SULT1B1 - liver; SULT1E1; CSN1S1)	Liver (FDCSP; PROL1; AMTN)	Uterine fibroids	UDP Glucuronosyltransferase Family 2 Members: UDP conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. UGT2B11 (estrogen metabolic process and xenobiotic glucuronidation); UGT2A1 and UGT2A2 (clearing lipophilic odorant molecules from the nasal sensory epithelium). // Sulfotransferase Family Members: Sulfate conjugation of many hormones, neurotransmitters, drugs, and xenobiotics. SULT1B1 ; SULT1E1 (transfers a sulfo moiety to and from estrone, which may control levels of estrogen receptors).	
12	(MECPP_MEHP); (MEHP_MEHP)	8	30424915	rs30424915:A:G	G	A	-0.0851	0.0189	7.74E-06	161	1	RBPMS	Intronic	INTS9; HMOX1; DUSP4; TMEM66; LEPROT1; MBOAT4; DCTN6; GTF2E; SMM18; GSR; PPP2CB; PURG; WRN	Several tissues but not liver or kidney (TMEM66; RBPMS; GTF2E; SMM18; GSR; PPP2CB)	Liver (TMEM66; LEPROT1; GTF2E; SMM18; PPP2CB; PURG); Bladder (MBOAT4; DCTN6)	None	GSR (Glutathione-Sulfide Reductase): Central enzyme of cellular antioxidant defence, and reduces oxidized glutathione disulfide (GSSG) to the sulphydryl form GSH, which is an important cellular antioxidant.	


920 **Figures**
921




922
923
924
925
926
927
928
929

Figure 1. Summary of the phthalate metabolites and ratios included in the study.


Diagram showing the phthalate metabolites included in the study, along with their precursor phthalates and intermediate metabolites. Low-molecular-weight metabolites (LWM) in the study are coloured in blue and high-molecular weight metabolites (HMW) in the study are coloured in green. Orange arrows represent the metabolic reactions whose ratio is included in the study (product/substrate).



930 **Figure 2. Miami plot of the association between common SNPs (top panel) and CNVs (bottom panel) vs**
 931 **phthalate levels or ratios**
 932 Each dot represents the association of a SNP or CNV. The x-axis indicates the position of the SNP or CNV in the
 933 genome. The y-axis shows the statistical significance, the $-\log_{10}(\text{p-value})$. Colours indicate the phthalate compound
 934 or ratio the SNPs or CNVs are associated with. The SNPs/CNVs passing multiple-testing correction ($5E-08$ for
 935 SNPs and $1.39E-03$ for CNVs) are annotated to the closest gene.
 936
 937



938 **Figure 3. Locus zoom of the SNP-associated regions identified after multiple-testing correction**
 939 Each dot represents the association of a SNP. The lead SNPs are coloured in dark purple, other lead SNPs (SNPs in
 940 the region with LD <0.1 with top lead SNP) in light purple and independent significant SNPs in red. Other SNPs are
 941 coloured according to their linkage disequilibrium (r^2) with the lead SNP. The y-axis shows the statistical
 942 significance, the $-\log_{10}(p\text{-value})$. The x-axis indicates the position of the SNP in the genome. FUMA prioritized
 943 coding genes and FUMA non-prioritized coding and non-coding genes are shown.
 944
 945
 946
 947
 948
 949
 950
 951
 952
 953



954
955 **Figure 4. Locus zoom of the consensus CNV-associated regions identified after multiple-testing correction**
956 Each line represents an CNV region in a single sample. Single gain CNVs are coloured in red, single loss CNVs in
957 blue and double loss CNVs in dark blue. The y-axis shows the number of individuals presenting a CNV for the
958 specific region. The x-axis shows the genomic coordinates. Rhombus represent the SNPs used to detect the CNVs,
959 and genes in the regions are also shown.